Synovial sarcoma (SS) is an aggressive cancer occurring mainly in young adults that contains in >95% of? cases a t(X;18) fusing SYT to either SSX1 or SSX2. The chimeric SYT-SSX product appears to function as? an aberrant transcriptional protein to deregulate gene expression but its critical target genes remain? unknown. In Project 4, we plan to integrate our existing Affymetrix expression profiling data with RNA? interference (RNAi), chromatin immunoprecipitation (ChrIP), bioinformatics, and re-sequencing to gain? insights into SS pathogenesis and to identify new methods for prognostication and targeted therapy.
Aim 1. ? Analysis of signaling pathways in SS. Leads provided by our expression profiling data into signaling? pathways involved in the biology of SS will be pursued, including the SHH/GLI, Wnt/beta-catenin, and? selected kinase pathways. Functional and mutational studies of these pathways will be performed and the? expression profiles associated with their activation will be determined.
Aim 2. Analysis of SYT-SSX-regulated? gene expression. To define the targets of SYT-SSX in SS, we will perform expression profiling of SYT-SSX? knockdown in SS cell lines and ChrIP analysis of candidate SYT-SSX targets. We will also use bioinformatic? approaches to identify recurrent motifs in the promoters of candidate SYT-SSX target genes drawn from the? same two sources. Such motifs might provide leads in identifying transcription factor families that interact? with SYT-SSX and mediate its effects. SYT-SSX target genes will then be validated as transcriptional? targets. Finally, selected SYT-SSX target genes will be evaluated as potential therapeutic targets by? assessing their role in SS growth using RNAi knockdown.
Aim 3. Development of expression profiling-based? clinical predictors in SS. Two approaches will be used to identify prognostically significant genes within the? expression profile of SS, using existing and prospective microarray data. First, a predictor of distant? recurrence-free survival will be developed and then combined with a new nomogram predictor based on? clinical variables. Secondly, the expression signature of metastatic potential will be defined based on? metastatic and non-metastatic SS samples and used to develop a prediction model for metastatic potential.? The genes composing these predictors may provide insights into the determinants of clinical behavior in SS? and opportunities for improved assignment of SS patients into high risk and low risk subgroups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047179-17
Application #
7645862
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
17
Fiscal Year
2008
Total Cost
$354,581
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2017) Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1. Genes Chromosomes Cancer 56:42-50
Seifert, Adrian M; Zeng, Shan; Zhang, Jennifer Q et al. (2017) PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res 23:454-465
Argani, Pedram; Zhang, Lei; Reuter, Victor E et al. (2017) RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol 41:655-662
Argani, Pedram; Zhong, Minghao; Reuter, Victor E et al. (2016) TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 40:723-37
Tan, Marcus C B; Brennan, Murray F; Kuk, Deborah et al. (2016) Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg 263:593-600
Specht, Katja; Zhang, Lei; Sung, Yun-Shao et al. (2016) Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40:433-42
Huang, Shih-Chiang; Ghossein, Ronald A; Bishop, Justin A et al. (2016) Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. Am J Surg Pathol 40:51-9
Dickson, Mark A; Schwartz, Gary K; Keohan, Mary Louise et al. (2016) Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2:937-40

Showing the most recent 10 out of 336 publications